145 related articles for article (PubMed ID: 3746385)
1. Response variability of human brain tumors to AZQ in tissue culture.
Kornblith PL; Rosa L; Bona JD; Edwards JA; Matuzic N; Hirschfeld A; Hawkins C
J Neurooncol; 1986; 4(1):49-54. PubMed ID: 3746385
[TBL] [Abstract][Full Text] [Related]
2. Effect of AZQ (1,4-cyclohexadiene-1,4-diacarbamic acid-2,5-bis(1-aziridinyl)-3,6 -dioxodiethylester) in recurring supratentorial malignant brain gliomas--a Phase II study. EORTC Brain Tumour Cooperative Group.
Eur J Cancer Clin Oncol; 1985 Jan; 21(1):143-6. PubMed ID: 4038653
[No Abstract] [Full Text] [Related]
3. Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.
Decker DA; Al Sarraf M; Kresge C; Austin D; Wilner HI
J Neurooncol; 1985; 3(1):19-21. PubMed ID: 2987424
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
Feun LG; Yung WK; Leavens ME; Burgess MA; Obbens EA; Bedikian AY; Savaraj N; Stewart DJ; Benjamin RS; Fields WS
J Neurooncol; 1984; 2(1):13-7. PubMed ID: 6088722
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.
Chamberlain MC; Prados MD; Silver P; Levin VA
J Neurooncol; 1988 Dec; 6(4):319-23. PubMed ID: 3221259
[TBL] [Abstract][Full Text] [Related]
6. Preliminary communication--treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ;NSC-182986).
Eagan RT; Dinapoli RP; Hermann RC; Groover RV; Layton DD
Am J Clin Oncol; 1983 Oct; 6(5):577-8. PubMed ID: 6613923
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with recurrent primary brain tumors with AZQ.
Schold SC; Friedman HS; Bjornsson TD; Falletta JM
Neurology; 1984 May; 34(5):615-9. PubMed ID: 6538653
[TBL] [Abstract][Full Text] [Related]
8. Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A Phase II study by the Illinois Cancer Council.
Haid M; Khandekar JD; Christ M; Johnson CM; Miller SJ; Locker GY; Merrill JM; Reisel H; Hatfield A; Lanzotti V
Cancer; 1985 Sep; 56(6):1311-5. PubMed ID: 4027870
[TBL] [Abstract][Full Text] [Related]
9. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumors.
Eagan RT; Dinapoli RP; Cascino TL; Scheithauer B; O'Neill BP; O'Fallon JR
J Neurooncol; 1987; 5(4):309-14. PubMed ID: 3440875
[TBL] [Abstract][Full Text] [Related]
11. The pharmacology of diaziquone given in intravenous or intracarotid infusion to normal and intracranial tumor-bearing puppies.
Egorin MJ; Bellis EH; Salcman M; Collins JM; Spiegel JF; Bachur NR
J Neurosurg; 1984 May; 60(5):1005-13. PubMed ID: 6716135
[TBL] [Abstract][Full Text] [Related]
12. Phase I-II diaziquone chemotherapy in brain tumors.
Madajewicz S; Spaulding M; Bhimani S; Avellanosa A; DeLos Santos R; Perry A; Zeigler P; Kirshner J
Cancer Treat Rep; 1984 Jun; 68(6):913-4. PubMed ID: 6733706
[No Abstract] [Full Text] [Related]
13. Treatment of metastatic breast cancer with AZQ: a phase II trial.
Martino S; Ratanatharathorn V; Samal BA; Singhakowinta A; Haas C
Cancer Invest; 1988; 6(3):289-91. PubMed ID: 3167612
[TBL] [Abstract][Full Text] [Related]
14. High dose AZQ in renal cancer. A Southwest Oncology Group phase II study.
Stephens RL; Kirby R; Crawford ED; Bukowski R; Rivkin SE; O'Bryan RM
Invest New Drugs; 1986; 4(1):57-9. PubMed ID: 3700042
[TBL] [Abstract][Full Text] [Related]
15. Toxicity of aziridinylbenzoquinone for aerobic and hypoxic cells of a transplanted mouse mammary tumor and interaction of the drug with radiation and adriamycin.
Tannock I
Cancer Res; 1983 May; 43(5):2059-62. PubMed ID: 6831436
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory small cell carcinoma of the lung.
Fuks JZ; Aisner J; Van Echo DA; Levitt M; Ihde DC; Carney D; Wiernik PH
Am J Clin Oncol; 1983 Apr; 6(2):171-3. PubMed ID: 6299094
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical evaluation of AZQ in renal cell carcinoma.
Decker DA; Kish J; Al-Sarraf M; Goldfarb S
Am J Clin Oncol; 1986 Apr; 9(2):126-8. PubMed ID: 3717078
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical evaluation of AZQ in adenocarcinoma of the lung.
Decker DA; Samson MK; Haas CD; Baker LH
Am J Clin Oncol; 1984 Aug; 7(4):353-5. PubMed ID: 6741865
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of diaziquone (AZQ) in advanced malignant melanoma.
Høst H; Joss R; Pinedo H; Bruntsch U; Cavalli F; Renard G; van Glabbeke M; Rozencweig M
Eur J Cancer Clin Oncol; 1983 Feb; 19(2):295-8. PubMed ID: 6681775
[TBL] [Abstract][Full Text] [Related]
20. Response rate and toxicity with aziridinylbenzoquinone in patients with recurrent gliomas. A progress report.
Tapazoglou E; Kish J; Ensley J; Al-Sarraf M
Am J Clin Oncol; 1988 Aug; 11(4):474-8. PubMed ID: 3407628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
